A Biotech Bonanza! Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : A Biotech Bonanza!

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: Alys Hall who wrote (28)	10/29/1997 7:22:00 AM
From: F. Jay Abella, III	Read Replies (1) of 64

A+G - For what its worth, I am VERY interested in this discussion. G - Good analysis of the EXTRA products. However, keep in mind that this is only one facet of their strategy. Their product lines are a portfolio of risk, with the EXTRA products being tier II. With such a setup, they can capitalize on the nuances of the FDA regulations and stagger the risk for themselves and their investors at each step of the way. The structure of the company indicates to me that SUPG management KNOWS THE DRUG BUSINESS. A rarity in this industry indeed. What do you think of the capital structure of SUPG? FJA PS - Who will be your next company? I would suggest SUNP.

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next